Answers are grounded in this paper and cite their sources.
Final analysis shows improved survival outcomes in resectable esophageal squamous cell carcinoma, suggesting effective treatment options.
Tislelizumab with chemotherapy/chemoradiotherapy as neoadjuvant treatment for resectable ESCC yielded promising pCR rates and favorable survival outcomes with a tolerable safety profile in both PET-/CT-guided responders and PET nonresponders.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: